John Lawrence Wallace, a Senior Officer, Director and 10% Holder, acquired 144,759 Common Shares on a direct ownership basis at a price of $5.290 through a private transaction on March 1st, 2021. The insider also acquired 31,927 Common Shares on a control or direction basis for registered holder AltaPharm International Inc. at a price of $5.290 through a private transaction on March 1st, 2021. This represents a $934,669 investment into the company's shares and an account share holdings change of greater than 100%.
At the same price, Daniel Marcel Legault, CEO, Director and 10% Holder, acquired 86,576 Common Shares on a direct ownership basis. The insider also acquired 21,968 Common Shares on a control or direction basis for registered holder Schmed Enterprises Inc. This represents a $574,198 investment into the company's shares and an account share holdings change of greater than 100%.
Two other insiders also acquired shares.
Antibe Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.
No Comments